 Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to 450 million in total is expected for this particular deal. NDA Filing of omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction is expected any day now in early 2022. 